Biomoda to report lung cancer diagnostic trial results in early 2010
This article was originally published in Clinica
Biomoda has completed recruitment in a phase II study of its early-stage diagnostic for lung cancer, CyPath. The trial, which has enrolled over 500 patients with a history of heavy smoking, will now start analysing samples from already-diagnosed lung cancer patients. The Albuquerque, New Mexico company expects to have final data in the first half of 2010. CyPath is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. It is designed for routine screening of large populations. In the study, deep-lung sputum samples will be screened using both CyPath and traditional Pap staining, and patients will also have a CT scan – the current standard of care for lung cancer detection.